Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma

NCT ID: NCT00604890

Last Updated: 2025-02-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 186 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-03-31
• Study Completion Date: 2010-01-31

Brief Summary

The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the treatment of superficial basal cell carcinomas by API 31510 topical cream. The study population will include one hundred and sixty (160) otherwise healthy male or female adults with one or more histologically confirmed superficial basal cell carcinoma lesions. One target lesion with an area of less than one inch will be designated for study treatment.

Conditions

Superficial Basal Cell Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

1

Active cream, 3% AM \& PM

Group Type: EXPERIMENTAL

API 31510 3% Topical Cream

Intervention Type: DRUG

Topical treatment 3% active cream applied to the lesion

2

Placebo cream AM ; 3% active cream PM

Group Type: PLACEBO_COMPARATOR

API 31510 3% Topical Cream

Intervention Type: DRUG

Topical treatment 3% active cream applied to the lesion

Placebo

Intervention Type: OTHER

Topical treatment placebo applied to the lesion

3

Placebo cream AM; 1.5% active cream PM

Group Type: PLACEBO_COMPARATOR

API 31510 1.5% Topical Cream

Intervention Type: DRUG

Topical treatment 1.5% active cream applied to the lesion

Placebo

Intervention Type: OTHER

Topical treatment placebo applied to the lesion

4

Placebo AM and PM

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Topical treatment placebo applied to the lesion

Interventions

API 31510 3% Topical Cream

Topical treatment 3% active cream applied to the lesion

Intervention Type: DRUG

API 31510 1.5% Topical Cream

Topical treatment 1.5% active cream applied to the lesion

Intervention Type: DRUG

Placebo

Topical treatment placebo applied to the lesion

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Male or female adults ≥ 18 years of age
• Primary, histologically confirmed sBCC with a minimum area of 0.5 cm2 and with a maximum diameter of 2.0 cm target sBCC lesion suitable for excision
• Histological diagnosis made no more than 4 weeks prior to the screening visit
• Histological biopsy removed 25% or less of the target lesion
• No other dermatological disease in the sBCC target site or surrounding area
• Willing to refrain from using non-approved lotions or creams on the target site and surrounding area during the treatment period. Willing to refrain from washing the treated area for at least 8 hours following the application of study medication
• Willing to refrain from exposure to direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study
• Laboratory values for the tests listed in the Study Schedule on page 2 within the reference ranges as defined by the central laboratory, or "out of range" test results that are clinically acceptable to the investigator.
• Ability to follow study instructions and likely to complete all study requirements
• Written informed consent obtained, including consent for tissue to be examined and stored by the central dermatopathologist
• Written consent to allow photographs of the target sBCC lesion to be used as part of the study data
• For females of childbearing potential, a negative pregnancy test at screening and using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy)

Exclusion Criteria

• Pregnant or lactating
• Presence of known or suspected systemic cancer
• Histological evidence of nBCC, SCC, or any other tumor in the biopsy specimen
• Histological evidence of severe squamous metaplasia, infiltrative, desomoplastic or micronodular growth patterns in the biopsy specimen
• History of recurrence of the target sBCC lesion
• Evidence of dermatological disease or confounding skin condition in the treatment area, e.g., SCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema, xeroderma pigmentosa
• Concurrent disease or treatment that suppresses the immune system
• Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk
• Known sensitivity to any of the ingredients in the study medication
• Use of a tanning parlor or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the course of the study
• Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit
• Use of systemic retinoids within the 6 months prior to the screening period
• Treatment with systemic immunomodulators or immunosuppressants within the 6 months prior to the screening period
• Use of topical immunomodulators within 2 cm of the target BCC lesion within the 4 weeks prior to the screening period
• Treatment with the following topical agents within the 4 weeks prior to the screening visit: levulanic acid, 5-fluorouracil, coricosteroids, retinoids, diclofenac, hyaluronic acid, imiquimod
• Undergone a facial resurfacing procedure, i.e., chemical peel, laser resurfacing, dermabrasion, within the 6 months prior to the screening visit, if the target sBCC lesion is on the face
• Treatment with liquid nitrogen, surgical excision or curettage within 2 cm of the target sBCC lesion during the 4 weeks prior to the screening visit
• Elective surgery within 4 weeks prior to the screening visit, during the study, or 4 weeks after the treatment period
• Evidence of current chronic alcohol or drug abuse
• Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of the screening visit
• In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions of the protocol and complete the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BPGbio

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Wilson, MD

Role: PRINCIPAL_INVESTIGATOR

Education and Research Foundation

Locations

Burke Pharmaceuticals

Hot Springs, Arkansas, United States

Skin Surgery Medical Group, Inc.

San Diego, California, United States

Colorado Medical Research Center

Denver, Colorado, United States

Dermatology Associates and Research

Coral Gables, Florida, United States

Gwinnett Clinical Research

Snellville, Georgia, United States

Scott D. Glazer, M.D., S.C.

Buffalo Grove, Illinois, United States

Christie Clinic

Champaign, Illinois, United States

Long Island Skin Cancer and Dermatologic Surgery, PC

Smithtown, New York, United States

Oregon Dermatology and Research Center

Portland, Oregon, United States

Dermatology Clinical Research Center of San Antonio

San Antonio, Texas, United States

Education & Research Foundation

Lynchburg, Virginia, United States

Countries

United States

Other Identifiers

CTL0108

Identifier Type: -

Identifier Source: org_study_id